India, April 27 -- Johnson & Johnson (JNJ)today announced new data from Cohort 2 of the pivotal Phase 2b SunRISe-1 study evaluating TAR-200-an intravesical gemcitabine releasing system-for patients with certain types of bladder cancer. The study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after complete response.
The findings demonstrated the highest complete response rate without reinduction with more than half of responders remaining cancer-free for at least 12 months. These results highlight the potential of TAR-200 as a breakthrough for people with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-N...